Literature DB >> 21490247

Inhibition of the Epstein-Barr virus lytic cycle by protoapigenone.

Chao-Ping Tung1, Fang-Rong Chang2, Yang-Chang Wu3, Da-Wei Chuang3, Attila Hunyadi4,3, Shih-Tung Liu1.   

Abstract

Epstein-Barr virus (EBV) expresses two transcription factors, Rta and Zta, during the immediate-early stage of the lytic cycle to activate the transcription of early and late genes. This study finds that 0.31 mM protoapigenone from Thelypteris torresiana (Gaud.) inhibits the expression of EBV lytic proteins, including Rta, Zta, EA-D and VCA, in P3HR1 cells after lytic induction with 12-O-tetradecanoylphorbol-13-acetate and sodium butyrate. The lack of expression of EBV lytic proteins after protoapigenone treatment is attributed to the inhibition of the transactivation function of Zta because protoapigenone reduces the transactivation activity of Zta and Gal4-Zta, which contains the transactivation domain of Zta fused with Gal4. In contrast, protoapigenone does not affect the ability of Rta to activate a promoter that contains an Rta-response element, showing that the inhibition is unrelated to Rta. Furthermore, in a lactate dehydrogenase assay, protoapigenone is not toxic to P3HR1 cells at the concentrations that inhibit the function of Zta, showing that protoapigenone is valuable for studying the function of Zta and preventing EBV lytic proliferation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490247     DOI: 10.1099/vir.0.031609-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.

Authors:  Erik R Hill; Siva Koganti; Jizu Zhi; Cynthia Megyola; Alexandra F Freeman; Umaimainthan Palendira; Stuart G Tangye; Paul J Farrell; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 2.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

3.  Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis.

Authors:  Chung-Chun Wu; Mei-Shu Chen; Yu-Jhen Cheng; Ying-Chieh Ko; Su-Fang Lin; Ing-Ming Chiu; Jen-Yang Chen
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

4.  Less Cytotoxic Protoflavones as Antiviral Agents: Protoapigenone 1'-O-isopropyl ether Shows Improved Selectivity Against the Epstein-Barr Virus Lytic Cycle.

Authors:  Máté Vágvölgyi; Gábor Girst; Norbert Kúsz; Sándor B Ötvös; Ferenc Fülöp; Judit Hohmann; Jean-Yves Servais; Carole Seguin-Devaux; Fang-Rong Chang; Michael S Chen; Li-Kwan Chang; Attila Hunyadi
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

Review 5.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

Review 6.  Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.

Authors:  Hongde Li; Jianmin Hu; Xiangjian Luo; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cancer Sci       Date:  2018-06-13       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.